799 related articles for article (PubMed ID: 20821390)
1. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
2. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
3. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
4. A Refined Developability Classification System.
Rosenberger J; Butler J; Dressman J
J Pharm Sci; 2018 Aug; 107(8):2020-2032. PubMed ID: 29665381
[TBL] [Abstract][Full Text] [Related]
5. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
7. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
9. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Zhang T; Heimbach T; Lin W; Zhang J; He H
J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
[TBL] [Abstract][Full Text] [Related]
10. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
11. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.
Wu CY; Benet LZ
Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225
[TBL] [Abstract][Full Text] [Related]
12. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
13. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
Golovenko NIa; Borisiuk IIu
Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
[TBL] [Abstract][Full Text] [Related]
14. Predicting biopharmaceutical performance of oral drug candidates - Extending the volume to dissolve applied dose concept.
Muenster U; Mueck W; van der Mey D; Schlemmer KH; Greschat-Schade S; Haerter M; Pelzetter C; Pruemper C; Verlage J; Göller AH; Ohm A
Eur J Pharm Biopharm; 2016 May; 102():191-201. PubMed ID: 26955751
[TBL] [Abstract][Full Text] [Related]
15. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
16. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
17. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
Newby D; Freitas AA; Ghafourian T
Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
[TBL] [Abstract][Full Text] [Related]
18. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
19. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
20. Application of a Refined Developability Classification System.
Rosenberger J; Butler J; Muenster U; Dressman J
J Pharm Sci; 2019 Mar; 108(3):1090-1100. PubMed ID: 30389565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
